Funding Wizard

Performance Targets for Perovskite Photovoltaic Research, Development, and Demonstration Programs

To address ecological questions that cannot be resolved with short-term observations or experiments, NSF established the Long-Term Ecological Research Program (LTER) in 1980. Two components differentiate LTER research from projects supported by other NSF programs: 1) the research is located at specific sites chosen to represent major ecosystem types or natural biomes, and 2) it emphasizes the study of ecological phenomena over long periods of time based on data collected in five core areas. Long-term studies are critical to achieve an integrated understanding of how components of ecosystems interact as well as to test ecological theory. Ongoing research at LTER sites is expected to contribute to the development and testing of fundamental ecological theories and significantly advance understanding of the long-term dynamics of populations, communities and ecosystems. It often integrates multiple disciplines and, through cross-site interactions may examine patterns or processes over broad spatial scales. Recognizing that the value of long-term data extends beyond use at any individual site, NSF requires that data collected by all LTER sites be made publicly accessible. NSF currently supports 28 LTER sites. The program is on-going and proposals are periodically invited when a need is identified to balance the LTER portfolio or when funding opportunities arise to support new LTERs. These opportunities are announced through separate solicitations. This solicitation governs submission of renewal proposals for active LTER site awards.

Low-No ProgramThe Federal Transit Administration (FTA) announces the opportunity to apply for approximately $1.1 billion in competitive grants under the fiscal year (FY) 2022 Low or No Emission Grant Program (Low-No Program) (Federal Assistance Listing: 20.526) and approximately $372 million in FY 2022 funds under the Grants for Buses and Bus Facilities Program (Buses and Bus Facilities Program) (Federal Assistance Listing 20.526), subject to availability of appropriated funding. Synopses and full announcement will be posted on Grants.gov as funding opportunity ID FTA-001-TPM for Low-No applications and FTA-002-TPM for Buses and Bus Facilities applications. Proposals must be submitted electronically through Grants.gov website by 11:59 PM Eastern Time May 31, 2022.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) – 2022 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2022. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates, the full text of the ROSES-2022 solicitation, and the "Summary of Solicitation" as a stand-alone document, may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2022. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2022table2 and http://solicitation.nasaprs.com/ROSES2022table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH22ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on “C.8 Lunar Data Analysis (.PDF)” to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read “C.1 Planetary Science Research Program Overview (.PDF)” from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2022 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2022 RSS feed for amendments, clarifications, and corrections to at http://science.nasa.gov/researchers/sara/grant-solicitations/ROSES-2022, and (3) The ROSES-2022 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

The FY22 RCRP Resource and Community Development Award supports the development of resources that advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Major gaps in patient care of rare cancers include lack of communication and dissemination strategies for rare cancer research and clinical findings within communities; lack of therapeutics and mechanistic studies to inform treatment development; lack of research and clinical resources, including patient tissues, cell, and tumor models; and lack of infrastructure for sharing data and other resources. The intent of this funding opportunity is to develop platforms that can share resources and knowledge pertaining to available models, molecular pathways, and therapeutic approaches to facilitate collaboration and information sharing among stakeholders such as researchers, patients, caregivers, clinicians, and other members of the rare cancers community. Examples of platforms include, but are not limited to the following: • Building and sharing rare tumor biospecimen repository with clinical annotation • Databases/banks for centralizing and sharing data for patient registries that can be accessed globally • Centralizing and sharing research models and molecular data related to genomics/ transcriptomics/immune profiling/proteomics/metabolomics/methylomics/bioinformatics • Generating a data/reagent/model exchange program where researchers can list resources that they are willing to share and are tagged with indications that may be relevant • Platform to enable or leverage longitudinal studies of disease natural history and treatment response • Development of novel methods and systems for collection, sharing, and analysis of data or biospecimens Applicants should include a well-formulated project design based on a strong scientific rationale and clearly articulate how the proposed resource-platform or community development addresses an unmet need in rare cancer research. Applicants should explain the advantage of their approach to developing resources or community versus standard methodologies, techniques, or scopes. A clear plan for collaboration and data sharing needs to be demonstrated. It is critical to demonstrate how the outcome of the proposed project can benefit multiple rare cancers.

The intent of the FY22 PRARP TRA is to support translational research that will accelerate the movement of promising products and knowledge in AD/ADRD research into clinical applications, including healthcare products and interventions, technologies, behavioral modalities, social modalities, and/or clinical practice guidelines. This mechanism supports both preclinical-to-clinical translational research (e.g., studies of interventions and medical devices in preclinical systems) and clinical research-to-clinical care translation (e.g., comparative effectiveness, implementation science, healthcare services research). Observations that support a research idea may be derived from a laboratory discovery, population-based studies, or a clinician’s first-hand knowledge of patients and anecdotal data. Inclusion of preliminary data is required. Use of animal models, if applicable, must be fully justified for relevance to human health. Clinical research applications are required to include a community collaboration research element. Important aspects of this award mechanism include: Translational Potential: The PRARP does not view translational research as a one-way continuum from bench to bedside. The research plan is encouraged to involve a reciprocal flow of ideas and information between basic and clinical science or clinical and implementation science as appropriate. The application should detail steps to move the research along the research and development continuum. Relevance to Military Health: Projects must have relevance to military Service Members, Veterans, and/or their family members and care partners. Applicants are encouraged to integrate and/or align their research projects with Department of Defense (DOD) and/or Department of Veterans Affairs (VA) research laboratories and programs. Collaborations between researchers, at military or Veterans institutions and non-military institutions, are strongly encouraged. A list of websites that may be useful in identifying additional information about ongoing DOD and VA areas of research interest or potential opportunities for collaboration can be found in Appendix 2.

The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary statistical analyses of existing dental, oral or craniofacial database resources, or that develop needed statistical methodology for analyzing existing dental, oral or craniofacial databases.

The H6 program seeks to develop ultra-small, low-power, fieldable clocks that can maintain their timing precision for one week.

The MBRP CTRA is intended to support the rapid implementation of clinical research (including clinical trials) with the potential to significantly impact burn care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point-of-injury, or during the early, acute phase of burn injury. Impact: The overall impact of the proposed research is a key component of this award mechanism. The potential impact of the research, both short-term and long-term, in addressing one or more of the FY22 MBRP Focus Areas should be clearly described. High-impact clinical research will, if successful, significantly advance the burn research field and the care of burn-injured patients. To be competitive, the application must include a sound scientific rationale, logical reasoning, and a well-formulated, testable hypothesis.Relevance to Military Health: The proposed research must be relevant to Service Members, Veterans, military beneficiaries, and/or the American public. Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:• Explanation of how the project addresses an aspect of burn injuries relevant to the military• Description of how the results of the proposed research will address a military needCollaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique data and research resources that the partners bring to the research effort, ultimately advancing burn research which is of significance to the Service Member, military families, and the American public.Inclusion of preliminary data relevant to the proposed clinical research is required.The following are important aspects of the FY22 MBRP CTRA:• The proposed clinical research study must be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.• The proposed clinical research study is expected to begin no later than 9 months after the award date.• The application should demonstrate availability of, and access to, a suitable patient population that will support a meaningful outcome for the study.• The application should include a clearly articulated statistical analysis plan, appropriate statistical expertise on the research team, and a power analysis reflecting sample size projections that will answer the objectives of the study.• The application should include a Transition Plan (including potential funding and resources) showing how the product will progress to the next clinical phase and/or delivery to the market after the successful completion of the FY22 MBRP CTRA.• Funded studies that contain clinical trials are required to register the study in the National Institutes of Health (NIH) clinical trials registry, www.clinicaltrials.gov, prior to initiation of the study. Refer to the General Application Instructions, Appendix 1, Section C, for further details. • If proposing a clinical trial that involves the use of a drug that has not been approved by the Food and Drug Administration (FDA) for the proposed investigational use, an Investigational New Drug (IND) application to the FDA that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) may be required and must be submitted to the FDA within 2 months (60 calendar days) of the award date. The IND should be specific for the product (i.e., the product should not represent a derivative or alternate version of the investigational agent described in the IND) and indication to be tested in the proposed clinical trial.• If the investigational product is a device, evidence that an Investigational Device Exemption (IDE) application that meets all requirements under 21 CFR 812 has been submitted to the FDA within 2 months (60 calendar days) of the award date, or that the device is exempt or qualifies for an abbreviated IDE, is required. The IDE should be specific for the device (i.e., should not represent a derivative or modified version of the device described in the IDE application) and indication to be tested in the proposed clinical trial.• If an IND or IDE has already been obtained for the investigational product, provide a copy of the acceptance from the FDA. The government reserves the right to withdraw funding if an IND or IDE is necessary but has not been submitted to the FDA within 2 months (60 calendar days) of the award date, or if documented status of the IND or IDE has not been obtained within 2 months (60 calendar days) of the award date.Only clinical research and/or clinical trials will be considered for funding under this mechanism.Funding from this award mechanism must support clinical research involving human subjects; animal research is not allowed under this funding opportunity.Applications to the FY22 MBRP CTRA must include clinical research, and may include initial proof of concept clinical trials, prospective studies involving use of human anatomical substances, observational studies, and/or involve some retrospective analysis of clinical data repositories.A clinical research study is defined as: (1) Patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: (a) mechanisms of human disease, (b) therapeutic interventions, (c) clinical trials, and (d) development of new technologies. (2) Epidemiologic and behavioral studies. (3) Outcomes research and health services research. Note: Studies that meet the requirements for Institutional Review Board (IRB) Exemption 4 are not considered CDMRP-defined clinical research. IRB Exemption 4 refers to research involving the collection or study of existing de-identified specimens or data, if these sources are publicly available.A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm.Funded trials are required to post a copy of the IRB-approved informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219.The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the DOD during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY22 MBRP CTRA Award will not exceed $2.21M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards will be made no later than September 30, 2023. For additional information refer to Section II.F.1, Federal Award Notices.The CDMRP expects to allot approximately $4.42M to fund approximately two Clinical Translational Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY22 funding opportunity will be funded with FY22 funds, which will expire for use on September 30, 2028.Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Research Protections, Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local IRB or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. Allow up to 3 months to complete the HRPO regulatory review and approval process following submission of all required and complete documents to the HRPO. Refer to the General Application Instructions, Appendix 1, and the Human Research Protections Office Resources and Overview document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.Multi-Institutional Clinical Studies: If the proposed research involves more than one institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.Use of DOD or Department of Veterans Affairs (VA) Resources: If the proposed research involves access to active-duty military or VA patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.Encouraged DOD and/or VA Collaboration and Alignment: Military relevance is a key feature of this award. Therefore, Principal Investigators (PIs) are encouraged to collaborate, integrate, and/or align their projects with military and/or VA research laboratories and programs. Although not a comprehensive list, Appendix 2 lists websites that may be useful in identifying information about DOD and VA areas of research interest, ongoing research, or potential opportunities for collaboration.The CDMRP intends that information, data, and research resources generated under awards funded by this program announcement be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 2, Section K.

The Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer. This award requires a team-based approach by a consortium of exceptional researchers and advocates, whose collaborative efforts will make a transformative impact in breast cancer. The transformation intended by the consortium must be in people’s lives, and not in the healthcare or research system. The consortium should have at least four, but no more than five, project teams, each investigating different projects under a central hypothesis. No more than two project teams may be based at one institution. Each team’s work must be integrated within the consortium so that every component is working toward the consortium’s central hypothesis. Note: This award is not intended to replace, supplement, duplicate, or compete with other collaborative research efforts, such as the National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPOREs), and it should not represent a collection of related Program Project grants or subprojects. The proposed consortium’s overall work is expected to be innovative. In addition, the Transformative Breast Cancer Consortium Award will include funds for “seed projects” to pursue brand new, high-risk/high-reward concepts that arise from the work, during the award period. If the work proposed meets the criteria or scope of one of the FY22 BCRP Breakthrough Awards, it is not appropriate for the Transformative Breast Cancer Consortium Award mechanism. The Breast Cancer Landscape describes the reality of breast cancer and identifies overarching challenges to progress the field. Research funded under this award mechanism should result in answers transform and disrupt the present landscape. Applications submitted to the Transformative Breast Cancer Consortium Award must include the following: · Research that includes truly innovative and brand-new, paradigm-shifting work in breast cancer that will address vital issues in a unique way. The issues may be one (or more) of the FY22 BCRP Overarching Challenges or, with justification, may be a different issue that meets the intent of the award mechanism and addresses the mission of ending breast cancer. If the application identifies a different fundamental issue, it must be coupled with at least one of the FY22 BCRP Overarching Challenges. · Research that includes different disciplines that come together to address ending breast cancer with an ecologic approach. The consortium’s proposed research must look at all aspects of the disease and bring together these different perspectives into one overarching plan for a deep, definitive dive into the FY22 BCRP Overarching Challenge(s) or other fundamental issue identified in the application. The plan also should include issues related to the hypothesis that have not been previously addressed or answered. · A plan that describes in detail the integration across the consortium in all aspects, including administration, logistics, and substance. Applications must describe the substantive integration across and among teams that are necessary for the work. The required communication plan and administrative management plan will not suffice to show integration, nor will identifying individual team members who will cross teams. A detailed explanation of the substantive research processes that will be integrated is required. Synergistic, highly integrated, multidisciplinary, and multi-institutional research teams of leading scientists, clinicians, and consumer advocates must be assembled into a consortium to address a major problem in a way that could not be accomplished by a single investigator or group. While the project teams are made up of different groups, each with its own Principal Investigator (PI), the teams must be working on the major problem identified in the Transformative Breast Cancer Consortium Award application and under the leadership of the Consortium Director. The research proposed in Transformative Breast Cancer Consortium Award applications may include phase 1 clinical trials and collaborations with pharmaceutical or biotechnology industry scientists and/or companies, as appropriate. However, a clinical trial is not required, and the primary of the application should not be a clinical trial. Although not all inclusive, applications that propose the following as the primary effort(s) or central hypothesis of the consortium will not meet the intent of this award mechanism: · NCI Program Project or SPORE grants or applications · Conducting drug screens or testing a “cocktail” of therapeutics · Targeting a single gene or protein · Developing a new derivative or formulation of an old drug · Conducting genomic landscape mapping analyses · Seeking to improve existing technologies (e.g., mammography or magnetic resonance imaging screening)